Concepedia

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Hiroyuki Murai, Akiyuki Uzawa, Yasushi Suzuki, Tomihiro Imai, Hirokazu Shiraishi, Hidekazu Suzuki, Meinoshin Okumura, Fanny O’Brien, Jingjing Wang, Kenji P. Fujita,

Journal of the Neurological Sciences · 2019 · 23 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

, , +17

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, Neal S. Young, Jörg Schubert et al. · New England Journal of Medicine · 2006 · 1.3K citations · Full text

, , +17

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Russell P. Rother, Scott A. Rollins, Christopher F. Mojcik et al. · Nature Biotechnology · 2007 · 764 citations

, , +13

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Christoph Licht, Larry A. Greenbaum, Petra Muus et al. · Kidney International · 2015 · 415 citations · Full text

, , +17